ID: ALA4203014

Max Phase: Preclinical

Molecular Formula: C23H14ClN2NaO3

Molecular Weight: 402.84

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(Nc1ccc(Cl)cc1C(=O)[O-])c1cccc(-c2cnc3ccccc3c2)c1.[Na+]

Standard InChI:  InChI=1S/C23H15ClN2O3.Na/c24-18-8-9-21(19(12-18)23(28)29)26-22(27)16-6-3-5-14(10-16)17-11-15-4-1-2-7-20(15)25-13-17;/h1-13H,(H,26,27)(H,28,29);/q;+1/p-1

Standard InChI Key:  SCPQMKAMLUPKEK-UHFFFAOYSA-M

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 402.84

Molecular Weight (Monoisotopic): 402.0771

AlogP: 5.51

#Rotatable Bonds: 4

Polar Surface Area: 79.29

Molecular Species: ACID

HBA: 3

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 3.28

CX Basic pKa: 4.13

CX LogP: 4.80

CX LogD: 2.38

Aromatic Rings: 4

Heavy Atoms: 29

QED Weighted: 0.47

Np Likeness Score: -1.36

References

1. Yamaoka N, Murano K, Kodama H, Maeda A, Dan T, Nakabayashi T, Miyata T, Meguro K..  (2018)  Identification of novel plasminogen activator inhibitor-1 inhibitors with improved oral bioavailability: Structure optimization of N-acylanthranilic acid derivatives.,  28  (4): [PMID:29366646] [10.1016/j.bmcl.2017.11.016]

Source

Source(1):

• Scientific Literature